Nifedipine Ratiopharm (Nifedipine)

Nifedipine blocks L‑type calcium channels on vascular smooth muscle and cardiac cells. This reduces calcium entry, causing arterial dilation, lowering peripheral resistance, and decreasing myocardial oxygen consumption, which helps control blood pressure and eases chest pain.

The appropriate dose of Nifedipine Ratiopharm is determined by the prescribing healthcare professional based on the individual’s condition, response, and any concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nifedipine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details, and any necessary import documentation.

Nifedipine, as a dihydropyridine calcium channel blocker, primarily causes arterial vasodilation, whereas beta‑blockers reduce heart rate and ACE inhibitors block angiotensin‑II formation. Nifedipine is often chosen when rapid blood‑pressure reduction is needed or when patients experience side‑effects from other classes.

Store the tablets at temperatures below 25 °C in their original packaging, protecting them from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Nifedipine Ratiopharm is taken orally, usually with a full glass of water. Tablets should be swallowed whole and not crushed, chewed, or broken unless specifically instructed by a healthcare professional.

Serious adverse events include severe hypotension, myocardial infarction, life‑threatening arrhythmias, and allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience sudden weakness, chest pain, irregular heartbeat, or signs of a severe allergic reaction.

Nifedipine Ratiopharm is contraindicated in patients with known hypersensitivity to nifedipine or other calcium channel blockers, those with severe hypotension, cardiogenic shock, recent myocardial infarction, or unstable angina. It should also be avoided in individuals with certain severe cardiac conduction disorders unless directed by a specialist.